CS0159

DRUG6 trials

Conditions

Diabetes Mellitus, Type 2Metabolic Dysfunction-Associated Steatohepatitis (MASH)Non-alcoholic Fatty Liver DiseaseObesityPrimary Biliary CholangitisPrimary Sclerosing CholangitisPrimary Sclerosing Cholangitis (PSC)Type 2 Diabetes

Phase 1

Study in Healthy Volunteers to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CS0159

CompletedNCT05082779

Cascade Pharmaceuticals, IncPrimary Sclerosing Cholangitis (PSC)

Start: 2021-10-26End: 2022-10-12Updated: 2022-10-18

Study to Evaluate Safety, Tolerability and Pharmacokinetics of CS0159 in Chinese Healthy Subjects

CompletedNCT05624294

Cascade Pharmaceuticals, IncPrimary Biliary Cholangitis

Start: 2022-12-19End: 2023-03-28Updated: 2023-05-03

A Study of the Pharmacokinetics and Safety of CS0159 in Subjects With Hepatic Injury

CompletedNCT06888115

Cascade Pharmaceuticals, IncPrimary Biliary Cholangitis

Start: 2025-03-13End: 2025-06-03Updated: 2025-07-11

Phase 2

CS0159 in Chinese Patients With PSC (Primary Sclerosing Cholangitis)

Active, not recruitingNCT05896137

Cascade Pharmaceuticals, IncPrimary Sclerosing Cholangitis

Start: 2023-08-07End: 2026-05-01Target: 50Updated: 2026-03-13

Unknown Phase

Efficacy and Safety of CS0159 Combined With Semaglutide in MASH Patients With Obesity and T2DM

CompletedNCT06492330

Shanghai Jiao Tong University School of MedicineDiabetes Mellitus, Type 2, Metabolic Dysfunction-Associated Steatohepatitis (MASH), Obesity

Start: 2024-07-19End: 2025-04-22Updated: 2025-06-03

Efficacy, Safety, and Tolerability of CS0159 Combined With Semaglutide in MAFLD Patients With Obesity and T2DM

Not yet recruitingNCT07570810

Shanghai Jiao Tong University School of MedicineNon-alcoholic Fatty Liver Disease, Obesity, Type 2 Diabetes

Start: 2026-06-01End: 2026-12-31Target: 30Updated: 2026-05-06

Related Papers

A first-in-class pulsatile FXR agonist for bile-acid-related liver diseases.